<p>Entera Bio（纳斯达克代码：ENTX - 获取免费报告）于周五公布了季度财报。该公司报告每股收益为（$0.06），超出分析师一致预期的（$0.08）$0.02，Zacks 报道。</p>
<h2>Entera Bio 股价表现</h2>
<p>周五中午交易时，纳斯达克 ENTX 的股价下跌 $0.05，达到 $1.75。该公司的股票交易量为 55,218 股，而其平均交易量为 120,233 股。该公司的市值为 6262 万美元，市盈率为 -6.73，贝塔系数为 1.62。该公司的 50 日简单移动平均线为 $2.15，200 日简单移动平均线为 $2.02。Entera Bio 的一年低点为 $1.41，一年高点为 $3.35。</p>
<h2>分析师设定新目标价</h2>
<p>另外，HC Wainwright 在 3 月 18 日的研究报告中重申了对 Entera Bio 的 “买入” 评级，并设定了 $10.00 的目标价。</p>
<p><strong>阅读我们关于 Entera Bio 的最新报告</strong></p>
<h2>关于 Entera Bio</h2>
<p>（获取免费报告）</p>
<p>Entera Bio Ltd. 是一家临床阶段公司，专注于开发和商业化口服给药的肽和蛋白质治疗药物，以满足未满足的医疗需求。该公司的产品候选者包括 EB612，目前正在进行治疗甲状旁腺功能减退症的二期临床试验；以及 EB613，该药物已完成治疗骨质疏松症的二期临床试验，并正在进行治疗应力性骨折的一期临床试验。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票比 Entera Bio 更好</li>
<li>股票中的死亡交叉是什么？</li>
<li>为什么 Dollar Tree 的 Family Dollar 销售可能会引发复苏</li>
<li>即将到来的 IPO 股票锁定期，解释</li>
<li>摩根大通：银行业的 “英伟达” 准备获得更多收益？</li>
<li>专家股票交易心理学技巧</li>
<li>购买 Chewy 股票反转？现在是时候了</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Entera Bio 吗？</h2>
<p>在考虑 Entera Bio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Entera Bio 并不在名单上。</p>
<p>虽然 Entera Bio 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ENTX

<p>Entera Bio（纳斯达克代码：ENTX）报告的季度每股收益为（$0.06），超出分析师预期的（$0.08）$0.02。该股下跌$0.05，报$1.75，市值为$6262 万。HC Wainwright 的分析师维持 “买入” 评级，目标价为$10.00。Entera Bio 专注于开发口服给药的肽和蛋白质治疗药物，目前有针对甲状旁腺功能减退症和骨质疏松症的候选药物在临床试验中</p>

<p>Entera Bio (NASDAQ:ENTX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02, Zacks reports.</p>
<div class="lb-trans"><p>Entera Bio（纳斯达克代码：ENTX - 获取免费报告）于周五公布了季度财报。该公司报告每股收益为（$0.06），超出分析师一致预期的（$0.08）$0.02，Zacks 报道。</p>
</div><h2>Entera Bio Price Performance</h2>
<div class="lb-trans"><h2>Entera Bio 股价表现</h2>
</div><p>Shares of NASDAQ ENTX traded down $0.05 during mid-day trading on Friday, hitting $1.75. The company's stock had a trading volume of 55,218 shares, compared to its average volume of 120,233. The stock has a market cap of $62.62 million, a price-to-earnings ratio of -6.73 and a beta of 1.62. The company's fifty day simple moving average is $2.15 and its 200-day simple moving average is $2.02. Entera Bio has a one year low of $1.41 and a one year high of $3.35.</p>
<div class="lb-trans"><p>周五中午交易时，纳斯达克 ENTX 的股价下跌 $0.05，达到 $1.75。该公司的股票交易量为 55,218 股，而其平均交易量为 120,233 股。该公司的市值为 6262 万美元，市盈率为 -6.73，贝塔系数为 1.62。该公司的 50 日简单移动平均线为 $2.15，200 日简单移动平均线为 $2.02。Entera Bio 的一年低点为 $1.41，一年高点为 $3.35。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Separately, HC Wainwright restated a &#34;buy&#34; rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Tuesday, March 18th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 3 月 18 日的研究报告中重申了对 Entera Bio 的 “买入” 评级，并设定了 $10.00 的目标价。</p>
</div><p><strong>Read Our Latest Report on Entera Bio</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Entera Bio 的最新报告</strong></p>
</div><h2>About Entera Bio</h2>
<div class="lb-trans"><h2>关于 Entera Bio</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.</p>
<div class="lb-trans"><p>Entera Bio Ltd. 是一家临床阶段公司，专注于开发和商业化口服给药的肽和蛋白质治疗药物，以满足未满足的医疗需求。该公司的产品候选者包括 EB612，目前正在进行治疗甲状旁腺功能减退症的二期临床试验；以及 EB613，该药物已完成治疗骨质疏松症的二期临床试验，并正在进行治疗应力性骨折的一期临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Entera Bio</li>
<li>What is a Death Cross in Stocks?</li>
<li>Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback</li>
<li>Upcoming IPO Stock Lockup Period, Explained</li>
<li>JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>Buy the Chewy Stock Reversal? Here’s Why Now Is the Time</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Entera Bio 更好</li>
<li>股票中的死亡交叉是什么？</li>
<li>为什么 Dollar Tree 的 Family Dollar 销售可能会引发复苏</li>
<li>即将到来的 IPO 股票锁定期，解释</li>
<li>摩根大通：银行业的 “英伟达” 准备获得更多收益？</li>
<li>专家股票交易心理学技巧</li>
<li>购买 Chewy 股票反转？现在是时候了</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RU5UWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ENTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Entera Bio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Entera Bio 吗？</h2>
</div><p>Before you consider Entera Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Entera Bio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Entera Bio 并不在名单上。</p>
</div><p>While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Entera Bio 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Entera Bio（纳斯达克：ENTX）公布了财报结果